Endocrinology an d Nutrition Department, Hospital Clínic de Barcelona, Barcelona 08036, Spain.
CIBER de Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid 28029, Spain.
J Clin Endocrinol Metab. 2020 Jan 1;105(1). doi: 10.1210/clinem/dgz031.
Although preeclampsia (PE) is a well-established cardiovascular risk factor (CVRF) in the general population, its role in type 1 diabetes (T1D) has been scarcely studied. We assessed the association between PE and preclinical atherosclerosis in T1D.
We recruited 112 women without cardiovascular disease and last pregnancy ≥5 years before: (1) T1D and previous PE (T1D+/PE+; n = 28); (2) T1D without preeclampsia (T1D+/PE-; n = 28); (3) previous PE without T1D (T1D-/PE+; n = 28); and (4) controls (without T1D or PE; T1D-/PE-; n = 28). Groups were matched by age, several CVRFs, and diabetes duration and retinopathy (in T1D participants). Carotid intima-media thickness (IMT) and the presence of plaque (IMT ≥ 1.5 mm) were assessed by standardized ultrasonography protocol.
Mean age of the participants was 44.9 ± 7.8 years (14.3% hypertension and 21.4% active smokers). Groups including T1D (T1D+/PE+ and T1D+/PE-) more frequently presented hypertension and statin treatment (23.2% vs 5.4% and 37.5% vs 8.9%; respectively; P < 0.01), without differences in other CVRFs. Carotid plaques were observed in 20.5%. In multivariate models adjusted for age, CVRF, and statins, both T1D and PE showed a similar impact on the presence of plaque, with odds ratios (95% confidence interval), 5.45 (1.36-21.9) and 4.24 (1.04-17.3), respectively. Both entities showed an additive effect when combined, both in common carotid-IMT (T1D+/PE- or T1D-/PE+, β = 0.198; T1D+/PE+, β = 0.297) and in the presence of plaque (8.53 [1.07-68.2] and 28.1 [2.67-296.4], respectively).
Previous PE was independently associated with preclinical atherosclerosis in T1D. Further studies are needed to ascertain its usefulness for stratifying risk in T1D women.
尽管子痫前期(PE)是普通人群中公认的心血管风险因素(CVRF),但其在 1 型糖尿病(T1D)中的作用却鲜有研究。本研究旨在评估 PE 与 T1D 患者的亚临床动脉粥样硬化之间的关系。
我们招募了 112 名无心血管疾病且上次妊娠距当前≥5 年的女性:(1)T1D 合并既往 PE(T1D+/PE+;n=28);(2)T1D 无 PE(T1D+/PE-;n=28);(3)既往 PE 无 T1D(T1D-/PE+;n=28);和(4)对照组(无 T1D 或 PE;T1D-/PE-;n=28)。通过年龄、多种 CVRF、糖尿病病程和视网膜病变(T1D 患者)对各组进行匹配。采用标准化超声检查方案评估颈动脉内膜中层厚度(IMT)和斑块的存在(IMT≥1.5mm)。
参与者的平均年龄为 44.9±7.8 岁(14.3%高血压和 21.4%主动吸烟者)。包括 T1D(T1D+/PE+和 T1D+/PE-)的组更常出现高血压和他汀类药物治疗(23.2%比 5.4%和 37.5%比 8.9%;分别;P<0.01),但其他 CVRF 无差异。20.5%的患者有颈动脉斑块。在调整年龄、CVRF 和他汀类药物的多变量模型中,T1D 和 PE 对斑块的存在均具有相似的影响,比值比(95%置信区间)分别为 5.45(1.36-21.9)和 4.24(1.04-17.3)。当两者联合时,均表现出相加效应,包括颈总动脉-IMT(T1D+/PE-或 T1D-/PE+,β=0.198;T1D+/PE+,β=0.297)和斑块的存在(8.53[1.07-68.2]和 28.1[2.67-296.4])。
既往 PE 与 T1D 患者的亚临床动脉粥样硬化独立相关。需要进一步研究以确定其在 T1D 女性患者中分层风险的有用性。